A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-0507
Full Text
Open PDFAbstract
Available in full text
Date
July 26, 2012
Authors
Publisher
American Association for Cancer Research (AACR)